Stockreport

KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital

KemPharm, Inc.  (KMPH) 
Last kempharm, inc. earnings: 2/28 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.kempharm.com/investor-overview
PDF Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales KemPharm Will Host a Conference Call and Live Audi [Read more]